Faculty Opinions recommendation of The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.

Author(s):  
Ladislav Senolt
Sign in / Sign up

Export Citation Format

Share Document